---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-003910"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2025-06-16T23:59:59+00:00"
generated_at: "2026-05-19T07:22:12.244710+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BioCryst shareholders approve 11M share increase in stock incentive plan at annual meeting

## Summary
- Director George Abercrombie retired effective June 12, 2025 after 13 years; no disagreement cited.
- Shareholders approved amended Stock Incentive Plan, increasing shares available by 11,000,000 to 81,090,000 total.
- Advisory say-on-pay passed with 143.1M for vs 6.4M against; auditor Ernst & Young ratified with 174.7M for.
- Director nominees Steven Galson and Alan Levin re-elected with ~146M votes each.

## SEC filing metadata
- accession: 0001171843-25-003910
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2025-06-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184325003910/0001171843-25-003910-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184325003910/f8k_061625.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-003910
- JSON: https://secwatch.observer/filing/0001171843-25-003910.json
- Plain text: https://secwatch.observer/filing/0001171843-25-003910.txt

## Key facts
- Executive change
  George B. Abercrombie retired as Director at BIOCRYST PHARMACEUTICALS INC.
  - Action: retired
  - Role: Director
  source text: On June 11, 2025, George B. Abercrombie notified BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), of his intention to retire from the Board of Directors of the Company (the “Board”), effective as of the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/882796/000117184325003910/0001171843-25-003910-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.